Rafarma Pharmaceuticals Overview
Get informed when a big investor buys or sells
+ Follow128.70
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Rafarma Pharmaceuticals's peg ratio stands at 128.7. That is above the sector sector average of 9.98. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Rafarma Pharmaceuticals sits higher the its sector benchmark (9.98) with a PEG ratio of 128.7. That is roughly 1189.2% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether 128.7 is attractive depends on Rafarma Pharmaceuticals's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Rafarma Pharmaceuticals's PEG ratio evolved across reporting periods, while the comparison chart places RAFA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
